Literature DB >> 25723092

In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.

A C Groo1, M Bossiere, L Trichard, P Legras, J P Benoit, F Lagarce.   

Abstract

AIM &
METHODS: The aim of the present work was to encapsulate paclitaxel (Ptx) in various lipid nanocapsules (LNCs) formulations and then to compare their pharmacokinetics and efficacy on a subcutaneous isograft model in rats.
RESULTS: Three different Ptx formulations were obtained. Drug payloads ranged from 1.32 to 3.62 mg Ptx/g of formulation. After oral administration the area under concentration-time curve was higher (p < 0.05) if Ptx was encapsulated, (1,2 Distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(PEG)] (DSPE-PEG-NH2)) LNCs displaying the highest area under concentration-time curve (p < 0.05). Efficacy was better than control for standard LNCs after oral administration (p < 0.05) and for (DSPE-PEG-NH2) LNCs after intravenous administration. Despite good absorption, (DSPE-PEG-NH2) LNCs failed to remain efficient after oral route.
CONCLUSION: This study highlights the importance of efficacy studies paired to pharmacokinetic studies for nanomedicines.

Entities:  

Keywords:  cancer; nanoparticles; oral route; paclitaxel; pharmacodynamics; pharmacokinetics; rats

Mesh:

Substances:

Year:  2015        PMID: 25723092     DOI: 10.2217/nnm.14.124

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  7 in total

1.  Modified Lipid Nanocapsules for Targeted Tanshinone IIA Delivery in Liver Fibrosis.

Authors:  Asmaa A Ashour; Amal H El-Kamel; Doaa A Abdelmonsif; Hoda M Khalifa; Alyaa A Ramadan
Journal:  Int J Nanomedicine       Date:  2021-12-08

2.  Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study.

Authors:  Jaleh Varshosaz; Somayeh Taymouri; Ali Jahanian-Najafabadi; Arezoo Alizadeh
Journal:  IET Nanobiotechnol       Date:  2018-09       Impact factor: 1.847

3.  New In Vitro Coculture Model for Evaluating Intestinal Absorption of Different Lipid Nanocapsules.

Authors:  Norraseth Kaeokhamloed; Emillie Roger; Jérôme Béjaud; Nolwenn Lautram; Florence Manero; Rodolphe Perrot; Chadi Abbara; Marie Briet; Samuel Legeay
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

4.  Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide.

Authors:  Anne-Claire Groo; Nada Matougui; Anita Umerska; Patrick Saulnier
Journal:  Int J Nanomedicine       Date:  2018-11-15

5.  Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity.

Authors:  Thomas Briot; Emilie Roger; Naila Bou Haidar; Jerome Bejaud; Nolwenn Lautram; Catherine Guillet; Sylvain Thépot; Samuel Legeay; Frederic Lagarce
Journal:  Int J Nanomedicine       Date:  2019-03-26

6.  Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.

Authors:  Maha M Eissa; Riham M El-Moslemany; Alyaa A Ramadan; Eglal I Amer; Mervat Z El-Azzouni; Labiba K El-Khordagui
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

7.  Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503.

Authors:  Adrien Chouchou; Anne Aubert-Pouëssel; Christophe Dorandeu; Zahraa Zghaib; Pierre Cuq; Jean-Marie Devoisselle; Pierre-Antoine Bonnet; Sylvie Bégu; Carine Deleuze-Masquefa
Journal:  Int J Pharm Investig       Date:  2017 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.